TTD | Drug: D0PP6Y

Drug General Information
Drug ID	D0PP6Y
Former ID	DIB019226
Drug Name	compound 13a
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[532338]
Formula	C19H18N6O
InChI	InChI=1S/C19H18N6O/c1-3-17(24-5-7-26-8-6-24)4-2-14(1)16-9-20-19-18(12-23-25(19)13-16)15-10-21-22-11-15/h1-4,9-13H,5-8H2,(H,21,22)
InChIKey	WCDLCPLAAKUJNY-UHFFFAOYSA-N
PubChem Compound ID	60182393
PubChem Substance ID	163720400, 174516741, 175447068, 249565835
Target and Pathway
Target(s)	Vascular endothelial growth factor receptor 2	Target Info	Inhibitor	[532338]
	TGF-beta type II receptor	Target Info	Inhibitor	[532338]
	activin A receptor, type I	Target Info	Inhibitor	[532338]
	AMP-activated protein kinase	Target Info	Inhibitor	[532338]
	Activin receptor-like kinase-1	Target Info	Inhibitor	[532338]
	Bone morphogenetic protein receptor	Target Info	Inhibitor	[532338]
KEGG Pathway	Ras signaling pathway
	Rap1 signaling pathway
	Cytokine-cytokine receptor interaction
	Endocytosis
	PI3K-Akt signaling pathway
	VEGF signaling pathway
	Focal adhesion
	Proteoglycans in cancerhsa04010:MAPK signaling pathway
	FoxO signaling pathway
	TGF-beta signaling pathway
	Osteoclast differentiation
	Hippo signaling pathway
	Adherens junction
	Chagas disease (American trypanosomiasis)
	HTLV-I infection
	Pathways in cancer
	Transcriptional misregulation in cancer
	Colorectal cancer
	Pancreatic cancer
	Chronic myeloid leukemiahsa04068:FoxO signaling pathway
	Regulation of autophagy
	mTOR signaling pathway
	AMPK signaling pathway
	Circadian rhythm
	Insulin signaling pathway
	Adipocytokine signaling pathway
	Oxytocin signaling pathway
	Glucagon signaling pathway
	Non-alcoholic fatty liver disease (NAFLD)
	Hypertrophic cardiomyopathy (HCM)hsa04060:Cytokine-cytokine receptor interaction
	Signaling pathways regulating pluripotency of stem cells
NetPath Pathway	IL2 Signaling PathwayNetPath_25:FSH Signaling Pathway
NetPath Pathway	IL2 Signaling Pathway
PANTHER Pathway	Angiogenesis
PANTHER Pathway	VEGF signaling pathwayP00052:TGF-beta signaling pathwayP00052:TGF-beta signaling pathway
Pathway Interaction Database	HIF-2-alpha transcription factor network
	Beta3 integrin cell surface interactions
	Signaling events mediated by TCPTP
	SHP2 signaling
	S1P1 pathway
	VEGF and VEGFR signaling network
	Integrins in angiogenesis
	Signaling events mediated by VEGFR1 and VEGFR2
	Notch-mediated HES/HEY networkglypican_1pathway:Glypican 1 network
	ALK1 signaling events
	TGF-beta receptor signalingalk1_2pathway:ALK1 pathway
Reactome	Neurophilin interactions with VEGF and VEGFR
	VEGF binds to VEGFR leading to receptor dimerization
	Integrin cell surface interactions
	EPHA-mediated growth cone collapse
	VEGFA-VEGFR2 Pathway
	VEGFR2 mediated cell proliferationR-HSA-2173789:TGF-beta receptor signaling activates SMADs
	TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
	SMAD2/3 Phosphorylation Motif Mutants in Cancer
	SMAD2/3 MH2 Domain Mutants in Cancer
	TGFBR2 Kinase Domain Mutants in Cancer
	TGFBR1 KD Mutants in Cancer
	TGFBR1 LBD Mutants in CancerR-HSA-1445148:Translocation of GLUT4 to the plasma membrane
	Macroautophagy
	Activation of PPARGC1A (PGC-1alpha) by phosphorylation
	TP53 Regulates Metabolic Genes
WikiPathways	Focal Adhesion
	Nifedipine Activity
	Cardiac Progenitor Differentiation
	Signaling by VEGF
	AngiogenesisWP560:TGF Beta Signaling Pathway
	MAPK Signaling Pathway
	TGF beta Signaling Pathway
	NRF2 pathway
	Nuclear Receptors Meta-Pathway
	Extracellular vesicle-mediated signaling in recipient cells
	Signaling by TGF-beta Receptor Complex
	miR-targeted genes in squamous cell - TarBase
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
	miR-targeted genes in adipocytes - TarBase
	Integrated Breast Cancer PathwayWP481:Insulin Signaling
	Energy dependent regulation of mTOR by LKB1-AMPK
	JAK/STAT
	BDNF signaling pathway
	Leptin signaling pathway
	SREBF and miR33 in cholesterol and lipid homeostasis
	SREBP signalling
	Signaling by Insulin receptor
	TOR Signaling
	AMPK SignalingWP474:Endochondral Ossification
	Ectoderm Differentiation
	Mesodermal Commitment Pathway
	Endoderm Differentiation
	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
	Hair Follicle Development: Induction (Part 1 of 3)
	Signaling by BMP
	Integrated Breast Cancer Pathway
	Heart Development
	BMP Signalling and Regulation
References
Ref 532338	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
Ref 532338	Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information